Group 1: Financial Performance - In 2025, the company achieved a revenue of 9.784 billion yuan, a year-on-year decrease of 18.62% [3] - The net profit attributable to shareholders was 891 million yuan, down 13.62% year-on-year; the net profit after deducting non-recurring gains and losses was 769 million yuan, a decrease of 21.86% [3] - The raw material drug segment reported a revenue of 6.165 billion yuan, a decline of 28.74% year-on-year, with a gross profit of 834 million yuan, down 35.59% [5] - The pharmaceutical segment generated a revenue of 1.155 billion yuan, a decrease of 18.42%, with a gross profit of 708 million yuan, down 7.3% [6] Group 2: CDMO Business Growth - The CDMO segment achieved a revenue of 2.198 billion yuan, a year-on-year increase of 16.66%, with a gross profit of 994 million yuan, up 28.54% [3] - The gross margin for the CDMO segment was 45.24%, an increase of 4.18 percentage points year-on-year [3] - The number of ongoing CDMO projects reached 1,311, a 32% increase year-on-year, with 398 commercialized projects, up 12% [4] - The company has signed confidentiality agreements with 713 innovative drug companies, an increase of 141 from the previous year [4] Group 3: R&D and Innovation - R&D expenditure for 2025 was 659 million yuan, a year-on-year increase of 2.79% [7] - The company has 1,326 R&D personnel, with 55 holding PhDs and 559 holding master's degrees, making up nearly 20% of the workforce [7] - The company plans to maintain a steady annual increase of 5% to 8% in R&D investment to support CDMO business growth and new technology fields [12] Group 4: Market Conditions and Challenges - The pharmaceutical industry environment remains challenging, heavily influenced by industry policies, particularly centralized procurement [3] - The overall raw material drug industry is in a downturn, with significant price pressures affecting sales [5] - The company anticipates continued improvement in the raw material drug business in 2026 after a challenging 2025 [6] Group 5: Future Outlook - The company expects to deliver over 6 billion yuan in commercialized orders within the next three years for the CDMO business [11] - The company aims to scale its medical beauty and cosmetic raw materials business to 1 billion yuan within three to five years [10] - The company plans to balance shareholder returns with the funding needs for CDMO business expansion, with over 92% of profits allocated for dividends in 2025 [15]

Summary of Yabon's Conference Call Company Overview - **Company**: Yabon Chemical - **Industry**: Pharmaceutical and Agrochemical CDMO (Contract Development and Manufacturing Organization) Key Points and Arguments 1. **Strategic Partnerships**: Yabon is implementing a major client strategy by establishing strategic partnerships with leading global pharmaceutical and agrochemical companies, focusing on innovative intermediates and derivative products in pharmaceuticals and agrochemicals [2][3][6] 2. **Business Development Strategy**: The company has adopted a "2 Plus X" business development strategy, emphasizing innovative pharmaceutical and agrochemical CDMO services, while deepening relationships with top global enterprises [3][6][19] 3. **Production Capacity Recovery**: Following the 2019 Jiangsu incident, Yabon has expanded its production capacity through new bases in Fushun, Xiangyang, and the newly built Lanzhou base, successfully restoring and enhancing production capabilities [2][4][5] 4. **International Market Expansion**: Yabon is actively expanding its international market presence, with some raw materials already being supplied to global markets including Australia, South Korea, and Indonesia, with plans to further penetrate North and South America [4][5] 5. **Core Production Bases**: The company operates six core bases and two cooperative factories, with significant R&D capabilities located in Shanghai and Huzhou, and a newly established pilot base in Lanzhou [3][7][14] 6. **New Projects and Capacity**: Yabon plans to launch new projects in its Yancheng and Lanzhou bases, expecting to add 2,000 tons of intermediates and raw materials by 2025 to meet market demands [3][19][21][22] 7. **Collaboration with Major Clients**: Yabon has established a strategic collaboration with Heng Rui Pharmaceutical, focusing on innovative drug development, with plans to support multiple clinical projects [12][13][18] 8. **Challenges and Responses**: The company faces challenges from declining prices of major projects and the need for new projects to ramp up. Yabon is addressing these by optimizing production line layouts and ensuring efficient capacity utilization [25][26] Additional Important Content 1. **Technological Advancements**: Yabon is investing in synthetic biology, fluid chemistry, and green carbon reduction, enhancing its capabilities to support its CDMO business [2][3][6] 2. **Regulatory Compliance**: The company has established bases that comply with GMP standards, including its Malta facility, which is crucial for serving export-oriented clients [8][14] 3. **Future Development Plans**: Yabon aims to build a smart Mega factory within three years, enhancing its large-scale manufacturing capabilities and cost efficiency [19] 4. **Flexibility in Production**: The Lanzhou base offers flexible production capabilities, allowing for co-line production to meet diverse customer needs effectively [24] 5. **Market Adaptation**: Yabon is adapting to market changes by focusing on high-end intermediates and raw materials, ensuring a robust supply chain through strategic partnerships [9][18] This summary encapsulates the essential insights from Yabon's conference call, highlighting the company's strategic direction, operational advancements, and market positioning within the pharmaceutical and agrochemical sectors.